argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting
argenx (ARGX) presented clinical trial and real-world data for VYVGART® and VYVGART® Hytrulo at the American Academy of Neurology Annual Meeting 2025. The data demonstrates consistent, favorable safety profiles and sustained clinical improvements for patients with generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP).
Key highlights include:
- ADAPT-NXT data showed sustained clinical improvements through 126 weeks with biweekly or three-week dosing
- ADAPT-SC+ analyses demonstrated consistent safety and sustained efficacy through nine treatment cycles
- Comparative effectiveness study revealed VYVGART shows more favorable benefit-risk profile among immunomodulatory therapies
- ADHERE+ interim results support long-term efficacy and functional improvement in CIDP patients
- Phase 4 trial investigating transition from IVIg to VYVGART Hytrulo within one week
argenx (ARGX) ha presentato dati da studi clinici e dal mondo reale per VYVGART® e VYVGART® Hytrulo durante l'American Academy of Neurology Annual Meeting 2025. I dati dimostrano profili di sicurezza coerenti e favorevoli e miglioramenti clinici sostenuti per i pazienti con miastenia grave generalizzata (gMG) e polineuropatia demielinizzante infiammatoria cronica (CIDP).
I punti salienti includono:
- I dati di ADAPT-NXT hanno mostrato miglioramenti clinici sostenuti fino a 126 settimane con dosaggi bisettimanali o ogni tre settimane
- Le analisi di ADAPT-SC+ hanno dimostrato sicurezza coerente ed efficacia sostenuta attraverso nove cicli di trattamento
- Uno studio di efficacia comparativa ha rivelato che VYVGART presenta un profilo di rapporto beneficio-rischio più favorevole rispetto alle terapie immunomodulatorie
- I risultati intermedi di ADHERE+ supportano l'efficacia a lungo termine e il miglioramento funzionale nei pazienti con CIDP
- Uno studio di fase 4 sta indagando la transizione da IVIg a VYVGART Hytrulo entro una settimana
argenx (ARGX) presentó datos de ensayos clínicos y del mundo real para VYVGART® y VYVGART® Hytrulo en la Reunión Anual de la Academia Americana de Neurología 2025. Los datos demuestran perfiles de seguridad consistentes y favorables, así como mejoras clínicas sostenidas para pacientes con miastenia gravis generalizada (gMG) y polineuropatía desmielinizante inflamatoria crónica (CIDP).
Los aspectos más destacados incluyen:
- Los datos de ADAPT-NXT mostraron mejoras clínicas sostenidas durante 126 semanas con dosis quincenales o cada tres semanas
- Los análisis de ADAPT-SC+ demostraron seguridad consistente y eficacia sostenida a lo largo de nueve ciclos de tratamiento
- Un estudio de efectividad comparativa reveló que VYVGART muestra un perfil de beneficio-riesgo más favorable entre las terapias inmunomoduladoras
- Los resultados intermedios de ADHERE+ apoyan la eficacia a largo plazo y la mejora funcional en pacientes con CIDP
- Un ensayo de fase 4 investiga la transición de IVIg a VYVGART Hytrulo en una semana
argenx (ARGX)는 2025년 미국 신경학회 연례 회의에서 VYVGART® 및 VYVGART® Hytrulo에 대한 임상 시험 및 실제 데이터 발표했습니다. 데이터는 전신성 중증 근무력증(gMG) 및 만성 염증성 탈수초 다발신경병증(CIDP) 환자에게 일관되고 유리한 안전성 프로파일과 지속적인 임상 개선을 보여줍니다.
주요 하이라이트는 다음과 같습니다:
- ADAPT-NXT 데이터는 격주 또는 3주 간격 투여로 126주 동안 지속적인 임상 개선을 보여주었습니다.
- ADAPT-SC+ 분석은 9회의 치료 주기 동안 일관된 안전성과 지속적인 효능을 입증했습니다.
- 비교 효과 연구에서는 VYVGART가 면역조절 요법 중에서 더 유리한 이익-위험 프로파일을 나타낸다고 밝혔습니다.
- ADHERE+의 중간 결과는 CIDP 환자에서 장기 효능 및 기능적 개선을 지원합니다.
- IVIg에서 VYVGART Hytrulo로의 전환을 1주일 이내에 조사하는 4상 시험이 진행 중입니다.
argenx (ARGX) a présenté des données d'essais cliniques et du monde réel pour VYVGART® et VYVGART® Hytrulo lors de la Réunion Annuelle de l'Académie Américaine de Neurologie 2025. Les données montrent des profils de sécurité cohérents et favorables ainsi que des améliorations cliniques durables pour les patients atteints de myasthénie grave généralisée (gMG) et de polynévrite démyélinisante inflammatoire chronique (CIDP).
Les points clés incluent :
- Les données ADAPT-NXT ont montré des améliorations cliniques durables sur 126 semaines avec des dosages bihebdomadaires ou tous les trois semaines
- Les analyses ADAPT-SC+ ont démontré une sécurité cohérente et une efficacité soutenue sur neuf cycles de traitement
- Une étude de l'efficacité comparative a révélé que VYVGART présente un profil bénéfice-risque plus favorable parmi les thérapies immunomodulatrices
- Les résultats intermédiaires d'ADHERE+ soutiennent l'efficacité à long terme et l'amélioration fonctionnelle chez les patients atteints de CIDP
- Un essai de phase 4 examine la transition de l'IVIg à VYVGART Hytrulo dans un délai d'une semaine
argenx (ARGX) hat auf dem Jahrestreffen der American Academy of Neurology 2025 klinische Studien- und Real-World-Daten zu VYVGART® und VYVGART® Hytrulo präsentiert. Die Daten zeigen konsistente, günstige Sicherheitsprofile und nachhaltige klinische Verbesserungen bei Patienten mit generalisierter Myasthenia gravis (gMG) und chronischer entzündlicher demyelinisierender Polyneuropathie (CIDP).
Wichtige Highlights umfassen:
- Die ADAPT-NXT-Daten zeigten nachhaltige klinische Verbesserungen über 126 Wochen mit zweiwöchentlicher oder dreiwöchentlicher Dosierung
- Die Analysen von ADAPT-SC+ zeigten konsistente Sicherheit und nachhaltige Wirksamkeit über neun Behandlungszyklen
- Eine vergleichende Effektivitätsstudie ergab, dass VYVGART ein günstigeres Nutzen-Risiko-Profil unter den immunmodulatorischen Therapien aufweist
- Die vorläufigen Ergebnisse von ADHERE+ unterstützen die langfristige Wirksamkeit und funktionale Verbesserung bei CIDP-Patienten
- Eine Phase-4-Studie untersucht den Übergang von IVIg zu VYVGART Hytrulo innerhalb einer Woche
- Sustained clinical improvements through 126 weeks in ADAPT-NXT trial
- Favorable benefit-risk profile compared to other immunomodulatory therapies
- Consistent safety and efficacy through nine treatment cycles in ADAPT-SC+
- Successful long-term efficacy in CIDP treatment
- Potential risk of infections including urinary tract and respiratory infections
- Possibility of serious allergic reactions and decrease in blood pressure
- Risk of infusion-related reactions
Insights
argenx's presentation of extensive long-term data at AAN 2025 strengthens their leadership position in FcRn inhibition for autoimmune diseases. The company will showcase important evidence that could expand VYVGART's clinical adoption:
The data demonstrates sustained efficacy through 126 weeks with both biweekly and three-week dosing regimens, offering potential for individualized treatment approaches. This flexibility could increase physician comfort with prescribing VYVGART and improve patient adherence. Particularly impressive is the achievement of minimal symptom expression (MSE) in gMG patients, suggesting VYVGART can deliver substantial quality-of-life improvements.
The ADAPT-SC+ analyses establish argenx's largest safety dataset for any FcRn blocker in the field, a significant competitive advantage when physicians evaluate treatment options. The comparative effectiveness study explicitly positions VYVGART with a more favorable benefit-risk profile versus other immunomodulatory therapies.
For CIDP, the ADHERE+ extension study reinforces functional improvements, addressing a critical metric that matters to patients. The Phase 4 trial investigating transition from IVIg to VYVGART Hytrulo could facilitate patient switching, potentially expanding market share by offering a compelling alternative to the standard of care.
These collective insights support argenx's strategy to move VYVGART earlier in treatment paradigms, which would significantly expand the addressable patient population and boost commercial potential across both indications.
argenx's data presentation at AAN 2025 carries significant commercial implications that strengthen the company's market position in the growing autoimmune therapeutic space. The expanded long-term dataset represents a strategic asset that reinforces the durability thesis for VYVGART's revenue stream.
The 126-week efficacy data with multiple dosing options creates two valuable commercial advantages: it supports prescriber confidence for long-term use and enables personalized treatment regimens that could improve both patient satisfaction and adherence rates. Both factors typically correlate with stronger prescription persistence and market penetration.
The comparative effectiveness study claiming VYVGART's superior benefit-risk profile provides critical differentiation in an increasingly competitive FcRn landscape. This differentiator becomes particularly valuable as argenx works to defend market position against emerging competitors.
The CIDP indication expansion with demonstrated functional improvements addresses a substantial market opportunity. The IVIg-to-VYVGART switching study specifically targets conversion from the established standard of care worth
argenx's strategy to position VYVGART earlier in treatment paradigms represents a significant market expansion opportunity. Moving from later-line to earlier intervention would substantially increase the addressable patient population and potential lifetime value per patient. The safety data presented serves as important supportive evidence for this strategic goal, potentially accelerating adoption in earlier treatment settings.
- Largest safety data set on FcRn blocking demonstrates consistent, favorable safety profile of VYVGART and VYVGART Hytrulo
- gMG patients on VYVGART achieve rapid, substantial, and sustained efficacy across multiple dosing regimens, supporting individualized treatment approach
- ADHERE+ oral presentation builds upon evidence of VYVGART Hytrulo driving improved functional ability in CIDP
Amsterdam, the Netherlands – March 7, 2025 – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced clinical trial and real-world data for VYVGART® (efgartigimod alfa-fcab) and VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) will be presented at the American Academy of Neurology (AAN) Annual Meeting, taking place in San Diego, CA from April 5-9, 2025.
“Our goal is to help people living with rare autoimmune diseases feel and function the way they did before experiencing life with a debilitating condition. This year at AAN, we are sharing more evidence demonstrating the long-term benefits of VYVGART for patients living with gMG and CIDP,” said Luc Truyen, M.D., Ph.D., Chief Medical Officer at argenx. “Our breadth of data continues to support VYVGART as a leading biologic. It has a proven ability to achieve minimal symptom expression for gMG patients and reduce CIDP symptoms quickly while providing improved functional ability, all with a favorable safety profile. We look forward to engaging in the latest science at AAN to continue pushing the boundaries of helping patients live better.”
Abstracts at AAN will highlight real-world and clinical data demonstrating VYVGART’s sustained clinical improvements, including consistent functional improvement and a favorable safety profile. In addition, presentations support an individualized treatment approach and the ambition for VYVGART to reach patients earlier in the treatment paradigm.
- Additional dosing approaches achieve clinical improvements in gMG through 126 weeks: New data from ADAPT-NXT, investigating biweekly or every three-week dosing of VYVGART, demonstrated sustained clinical improvements, including minimal symptom expression (MSE), and consistent long-term safety through 126 weeks.
- Largest long-term data set of any FcRn blocker in gMG shows sustained safety and efficacy: ADAPT-SC+ analyses of VYVGART Hytrulo demonstrate consistent safety results and sustained efficacy through nine cycles of treatment.
- Favorable benefit-risk profile in gMG: A comparative effectiveness study of emerging immunomodulatory therapies for patients with gMG shows that Fc receptor blockers, particularly VYVGART, show a more favorable benefit-risk profile.
- Long-term effectiveness in CIDP: Interim results from the open-label extension ADHERE+ further build upon the largest clinical data set supporting long-term efficacy, including functional improvement and safety of VYVGART Hytrulo in CIDP.
- Switch from IVIg to efgartigimod in CIDP: The Phase 4 open-label trial is investigating effective and safe transition from stable IVIg doses to VYVGART Hytrulo within one week after last IVIg dose.
Details for oral and poster presentations at AAN are as follows:
| Title | Lead Author | Presentation |
| Long-term Efficacy of Efgartigimod PH20 SC in Patients with Chronic Inflammatory Demyelinating Polyneuropathy: Interim Results From The ADHERE+ Study | Jeffrey Allen | Oral Presentation #002 S:16 Updates on Nerve and Muscle Disorders Monday, April 7 1:12 PM |
| Design of a Phase 3 Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Subcutaneous Efgartigimod PH20 Administered by Prefilled Syringe in Adults with Ocular Myasthenia Gravis | Carolina Barnett-Tapia | Poster #003 Neighborhood 11 Saturday, April 5 11:45 - 12:45 PM |
| Long-Term Safety and Efficacy of Subcutaneous Efgartigimod PH20 in Adult Participants with Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC+ Study | Tuan Vu | Poster #005 Neighborhood 11 Saturday, April 5 11:45 - 12:45 PM |
| Fixed Cycle and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part B of ADAPT NXT | Kelly Gwathmey | Poster #004 Neighborhood 11 Saturday, April 5 11:45 - 12:45 PM |
| Hospitalization Outcomes After Efgartigimod Initiation In Patients with Myasthenia Gravis | A. Gordon Smith | Poster #011 Neighborhood 11 Saturday, April 5 11:45 – 12:45 PM |
| A Retrospective Claims Study to Investigate Safety Risks Associated with Chronic Inflammatory Demyelinating Polyneuropathy and the Mediating Effects of Immunoglobulin Treatments | Jana Podhorna | Poster #011 Neighborhood 2 Saturday, April 5 11:45 AM – 12:45 PM |
| Changes In Nonsteroidal Immunosuppressive Treatment Usage Before and After Efgartigimod Initiation in Patients with Myasthenia Gravis | Pushpa Narayanaswami | Poster #015 Neighborhood 11 Saturday, April 5 11:45 – 12:45 PM |
| Combined Analyses of Participants with Anti-Acetylcholine Receptor Seronegative Generalized Myasthenia Gravis Treated with Efgartigimod Across Clinical Studies | Vera Bril | Poster #029 Neighborhood 11 Saturday, April 5 11:45 - 12:45 PM |
| Evaluating the Comparative Effectiveness of Emerging Immunomodulatory Therapies for Patients with Generalized Myasthenia Gravis | A. Gordon Smith | Poster #033 Neighborhood 11 Saturday, April 5 11:45 – 12:45 PM |
| Study Design of Subcutaneous Efgartigimod PH20 in Juvenile Generalized Myasthenia Gravis | Abigail Schwaede | Poster #009 Neighborhood 6 Monday, April 7 5:00 - 6:00 PM |
| Phase 3 Trial Investigating Impact of Intravenous Efgartigimod in Anti-Acetylcholine Receptor Antibody Negative Generalized Myasthenia Gravis | James F. Howard Jr | Poster #032 Neighborhood 11 Monday, April 7 5:00 - 6:00 PM |
| First-in-Human Dose Selection and Pharmacokinetics, Safety, Tolerability, and Immunogenicity of ARGX-119, an Agonist Antibody for Human Muscle-Specific Kinase | Tonke van Bragt | Poster #007 Neighborhood 2 Tuesday, April 8 5:00-6:00 PM |
| Treatment Impact of Efgartigimod PH20 SC in I-RODS Daily Activity Assessment in Patients with Chronic Inflammatory Demyelinating Polyneuropathy: Post hoc Analysis of the Registrational ADHERE Study | Richard Lewis | Poster #025 Neighborhood 11 Tuesday, April 8 5:00 PM – 6:00 PM |
| Investigating the Pharmacodynamics, Injection Speed, and Usability of Subcutaneous Efgartigimod PH20 Administration Using a Prefilled Syringe | Tiffany Hargraves | Poster #026 Neighborhood 11 Tuesday, April 8 11:45 - 12:45 PM |
| Transition From Intravenous Immunoglobulin to Efgartigimod PH20 SC in Participants with Chronic Inflammatory Demyelinating Polyneuropathy: A Phase 4 Study in Progress | Yessar Hussain | Poster #026 Neighborhood 11 Tuesday, April 8 5:00 PM – 6:00 PM |
| COVID-19 Vaccination Response in Participants Across Clinical Trials Investigating Efgartigimod PH20 SC | Ali A. Habib | Poster #029 Neighborhood 11 Tuesday, April 8 11:45 - 12:45 PM |
More information on the program is available at www.aan.com/events/annual-meeting-abstracts#subnav.
See FDA-approved Important Safety Information below, full Prescribing Information for VYVGART, and full Prescribing Information for VYVGART Hytrulo for additional information.
Important Safety Information
What is VYVGART® (efgartigimod alfa-fcab)?
VYVGART is a prescription medicine used to treat a condition called generalized myasthenia gravis, which causes muscles to tire and weaken easily throughout the body, in adults who are positive for antibodies directed toward a protein called acetylcholine receptor (anti-AChR antibody positive).
IMPORTANT SAFETY INFORMATION
Do not use VYVGART if you have a serious allergy to efgartigimod alfa or any of the other ingredients in VYVGART. VYVGART can cause serious allergic reactions and a decrease in blood pressure leading to fainting.
VYVGART may cause serious side effects, including:
- Infection. VYVGART may increase the risk of infection. The most common infections were urinary tract and respiratory tract infections. Signs or symptoms of an infection may include fever, chills, frequent and/or painful urination, cough, pain and blockage of nasal passages/sinus, wheezing, shortness of breath, fatigue, sore throat, excess phlegm, nasal discharge, back pain, and/or chest pain.
- Allergic Reactions (hypersensitivity reactions). VYVGART can cause allergic reactions such as rashes, swelling under the skin, and shortness of breath. Serious allergic reactions, such as trouble breathing and decrease in blood pressure leading to fainting have been reported with VYVGART.
- Infusion-Related Reactions. VYVGART can cause infusion-related reactions. The most frequent symptoms and signs reported with VYVGART were high blood pressure, chills, shivering, and chest, abdominal, and back pain.
Tell your doctor if you have signs or symptoms of an infection, allergic reaction, or infusion-related reaction. These can happen while you are receiving your VYVGART treatment or afterward. Your doctor may need to pause or stop your treatment. Contact your doctor immediately if you have signs or symptoms of a serious allergic reaction.
Before taking VYVGART, tell your doctor if you:
- take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines,
- have received or are scheduled to receive a vaccine (immunization), or
- have any allergies or medical conditions, including if you are pregnant or planning to become pregnant, or are breastfeeding.
What are the common side effects of VYVGART?
The most common side effects of VYVGART are respiratory tract infection, headache, and urinary tract infection. These are not all the possible side effects of VYVGART. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1-800-FDA-1088.
Please see the full Prescribing Information for VYVGART and talk to your doctor.
What is VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc)?
VYVGART HYTRULO is a prescription medicine used to treat a condition called generalized myasthenia gravis, which causes muscles to tire and weaken easily throughout the body, in adults who are positive for antibodies directed toward a protein called acetylcholine receptor (anti-AChR antibody positive).
VYVGART HYTRULO is a prescription medicine used for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP)
IMPORTANT SAFETY INFORMATION
Do not use VYVGART HYTRULO if you have a serious allergy to efgartigimod alfa, hyaluronidase, or any of the other ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.
VYVGART HYTRULO may cause serious side effects, including:
- Infection. VYVGART HYTRULO may increase the risk of infection. The most common infections for efgartigimod alfa-fcab-treated patients were urinary tract and respiratory tract infections. Signs or symptoms of an infection may include fever, chills, frequent and/or painful urination, cough, pain and blockage of nasal passages/sinus, wheezing, shortness of breath, fatigue, sore throat, excess phlegm, nasal discharge, back pain, and/or chest pain.
- Allergic Reactions (hypersensitivity reactions). VYVGART HYTRULO can cause allergic reactions such as rashes, swelling under the skin, and shortness of breath. Hives were also observed in patients treated with VYVGART HYTRULO. Serious allergic reactions, such as trouble breathing and decrease in blood pressure leading to fainting have been reported with efgartigimod alfa-fcab.
- Infusion-Related Reactions. VYVGART HYTRULO can cause infusion-related reactions. The most frequent symptoms and signs reported with efgartigimod alfa-fcab were high blood pressure, chills, shivering, and chest, abdominal, and back pain.
Tell your doctor if you have signs or symptoms of an infection, allergic reaction, or infusion-related reaction. These can happen while you are receiving your VYVGART HYTRULO treatment or afterward. Your doctor may need to pause or stop your treatment. Contact your doctor immediately if you have signs or symptoms of a serious allergic reaction.
Before taking VYVGART HYTRULO, tell your doctor if you:
- take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines,
- have received or are scheduled to receive a vaccine (immunization), or
- have any allergies or medical conditions, including if you are pregnant or planning to become pregnant, or are breastfeeding.
What are the common side effects of VYVGART HYTRULO?
The most common side effects in efgartigimod-alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. Additional common side effects with VYVGART HYTRULO are injection site reactions, including rash, redness of the skin, itching sensation, bruising, pain, and hives.
These are not all the possible side effects of VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1-800-FDA-1088.
Please see the full Prescribing Information for VYVGART HYTRULO and talk to your doctor.
About VYVGART
VYVGART is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG autoantibodies. It is the first approved FcRn blocker in the United States, EU, China and Canada for the treatment of adults with generalized myasthenia gravis (gMG) who are anti- acetylcholine receptor (AChR) antibody positive and in Japan for the treatment of adults with gMG who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs).
About VYVGART Hytrulo
VYVGART Hytrulo is a subcutaneous combination of efgartigimod alfa, a human IgG1 antibody fragment marketed for intravenous use as VYVGART, and recombinant human hyaluronidase PH20 (rHuPH20), Halozyme’s ENHANZE® drug delivery technology to facilitate subcutaneous injection delivery of biologics. In binding to the neonatal Fc receptor (FcRn), VYVGART Hytrulo results in the reduction of circulating IgG. It is the first-approved FcRn blocker administered by subcutaneous injection. VYVGART Hytrulo is the proprietary name in the U.S. for subcutaneous efgartigimod alfa and recombinant human hyaluronidase PH20. It may be marketed under different proprietary names following approval in other regions.
About Generalized Myasthenia Gravis
Generalized myasthenia gravis (gMG) is a rare and chronic autoimmune disease where IgG autoantibodies disrupt communication between nerves and muscles, causing debilitating and potentially life-threatening muscle weakness. Approximately
About Chronic Inflammatory Demyelinating Polyneuropathy
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare and serious autoimmune disease of the peripheral nervous system. Although confirmation of disease pathophysiology is still emerging, there is increasing evidence that IgG antibodies play a key role in the damage to the peripheral nerves. People with CIDP experience fatigue, muscle weakness and a loss of feeling in their arms and legs that can get worse over time or may come and go. These symptoms can significantly impair a person's ability to function in their daily lives. Without treatment, one-third of people living with CIDP will need a wheelchair.
About ARGX-119
ARGX-119 is a humanized agonistic monoclonal antibody (mAb) that targets and activates muscle-specific kinase (MuSK) to promote maturation and stabilization of the neuromuscular junction (NMJ). MuSK is a receptor kinase that has a critical role in the structure and function of the NMJ. ARGX-119 is being developed as a potential therapy for patients with neuromuscular disease.
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, X/Twitter, Instagram, Facebook, and YouTube.
References
1 Behin et al. New Pathways and Therapeutics Targets in Autoimmune Myasthenia Gravis. J Neuromusc Dis 5. 2018. 265-277
For further information, please contact:
Media:
Ben Petok
Bpetok@argenx.com
Investors:
Alexandra Roy (US)
aroy@argenx.com
Lynn Elton (EU)
lelton@argenx.com
Forward-looking Statements
The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements.” These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “aim,” “are,” “believe,” “can,” “continue,” “engage,” “may,” and “will” and include statements argenx makes concerning the potential impact of VYVGART and VYVGART Hytrulo for patients; the data for VYVGART and VYVGART Hytrulo that will be presented at the upcoming AAN Annual Meeting; its goal of pushing the boundaries of helping patients live better; the planned agenda for the AAN Annual Meeting; its data showing VYVGART and VYVGART Hytrulo as one of the leading biologics for gMG and CIDP; and its goal of translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx’s actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including but not limited to, the results of argenx’s clinical trials; expectations regarding the inherent uncertainties associated with the development of novel drug therapies; preclinical and clinical trial and product development activities and regulatory approval requirements; the acceptance of its products and product candidates by its patients as safe, effective and cost-effective; the impact of governmental laws and regulations on its business; its reliance on third-party suppliers, service providers and manufacturers; inflation and deflation and the corresponding fluctuations in interest rates; and regional instability and conflicts. A further list and description of these risks, uncertainties and other risks can be found in argenx’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx’s most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.
FAQ
What are the latest efficacy results for VYVGART in treating gMG patients?
How does VYVGART's safety profile compare to other gMG treatments?
What are the ADAPT-SC+ results for VYVGART Hytrulo?
How effective is VYVGART Hytrulo in treating CIDP patients?
Can patients switch from IVIg to VYVGART Hytrulo treatment?
